Bd gains 510(k) clearance of artificial intelligence software for mrsa diagnostics

Bd kiestra™ mrsa imaging application helps enhance microbiology laboratory efficiency and workflow franklin lakes, n.j. , may 16, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced 510(k) clearance from the u.s. food and drug administration (fda) for the new bd kiestra™ methicillin-resistant staphylococcus aureus (mrsa) imaging application that uses artificial intelligence (ai) to interpret bacterial growth and release negative specimens with minimal human interaction.
BDX Ratings Summary
BDX Quant Ranking